Alnylam Pharmaceuticals, Inc. (ALNY)

From the record

Alnylam Pharmaceuticals, Inc.'s filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

Alnylam Pharmaceuticals, Inc.'s 10 filed years say what it did: revenue went from $47 million in fiscal 2016 to $3.7 billion in fiscal 2025, up 62.4% a year; it rose in 8 of 9 years; the deepest fall was 17% from fiscal 2017 to fiscal 2018; net income was positive in 1 of 10 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Alnylam Pharmaceuticals, Inc.'s diluted share count grew about 3.4% a year, and dividends and buybacks returned about 0% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 268 sales (125 under scheduled 10b5-1 plans) and 2 purchases of their own stock on the open market in the year to 2026-11-12, buying about $543 thousand (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Alnylam Pharmaceuticals, Inc. earned about 40 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 61 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 84 cents per dollar of assets, and net share issuance: its share count grew 5.5% over the year (the filed statements).

From the record

Alnylam Pharmaceuticals, Inc.'s standing among 315 graded names in its industry family: revenue of $3.7 billion in fiscal 2025 ranks in the top 7% by size; a net margin of 8.4% ranks in the top 18%; revenue growth of 53% a year over the last 3 filed years ranks in the top 23% (its annual reports).

From the record

Alnylam Pharmaceuticals, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Greenstreet, Yvonne (Chief Executive Officer, as filed), filing under that title since 2022-01-04, 4.9 years (bottom 47% of its family); the 18 officers and directors filing in the last fifteen months have been on the record a median of 6.2 years (top 37%); 8 officer or director changes were reported on Form 8-K since 2023-11-13, against the 18 people in charge now (top 47%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Alnylam Pharmaceuticals, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $1.7 billion against no long-term debt tagged leaves 33.4% of its assets as net cash, top 44% of its family; cash from operations less capital spending is 12.5% of revenue (top 19%); a gross margin of 81.8% (top 31%); research spending of 35.5% of revenue (bottom 36%) (its annual report).

From the record

Alnylam Pharmaceuticals, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 53% a year over the last three filed years against 62.4% over all 10, slowing (bottom 35% of its family); the newest year grew 65.2% (top 21%); research spending grew 14.3% a year (top 32%); capital spending grew -6.6% a year (top 45%) (its annual reports). Alnylam Pharmaceuticals, Inc. reported 6 product lines in fiscal 2025: Amvuttra at $2.3 billion (62%), Collaborations at $553 million (15%), GIVLAARI at $308 million (8%), and 3 more; 5 of 6 grew against the year before (its annual report).

From the record

Alnylam Pharmaceuticals, Inc.'s newest year against its own record: revenue of $3.7 billion in fiscal 2025 came in 12.2% above the $3.3 billion its prior three years' pace pointed to (top 32% of its family); net income of $314 million against a prior three-year average of $617 million (top 10%); a net margin of 8.4% against -48.5% before (top 36%) (its annual reports).